Nasdaq approves the Canary Staked INJ ETF listing under ticker INJC. SEC registration must become effective before trading begins.
Author: Kritika Gupta
5th November 2026- Nasdaq has approved the listing application for the Canary Staked INJ ETF, which will trade under the ticker INJC. The approval appears in a Form 8-A that Canary filed with the SEC.
High Signal Summary For A Quick Glance
The Bullish Broke Guy X
@EthGoldi
@injective 90% staked sounds great until you ask who's actually buying $INJ for the yield and who's buying it for the ticker. INJC is a wrapper, not a use case.
BREAKING: The NASDAQ has officially approved the listing of the first-ever INJ Staked ETF. The ETF will bring unprecedented exposure to $INJ and will target staking 90% of its institutional holdings in the U.S. The ticker is INJC. https://t.co/Rb4HhOY29K
07:54 AM·Nov 5, 2026
Aerdronne
@Aedronne
@injective Huge step. Nasdaq listing approval for the first staked INJ ETF (INJC) with a 90% staking target is a real institutional on-ramp. Still waiting on the S-1 to go effective for actual trading, but this is the kind of regulated exposure that can meaningfully expand the buyer base.
BREAKING: The NASDAQ has officially approved the listing of the first-ever INJ Staked ETF. The ETF will bring unprecedented exposure to $INJ and will target staking 90% of its institutional holdings in the U.S. The ticker is INJC. https://t.co/Rb4HhOY29K
07:08 AM·Nov 5, 2026
vexor4i
@vexor4i
@injective NASDAQ listing with 90% staking target is a structural shift. INJC brings regulated yield exposure that institutions can actually allocate to. Watch the flow data post-launch → that tells the real story.
BREAKING: The NASDAQ has officially approved the listing of the first-ever INJ Staked ETF. The ETF will bring unprecedented exposure to $INJ and will target staking 90% of its institutional holdings in the U.S. The ticker is INJC. https://t.co/Rb4HhOY29K
05:40 AM·Nov 5, 2026
High attention and emotional sentiment detected.
So the milestone is real, but it is narrow. The filing clears INJC to list on Nasdaq. It does not yet let the fund sell shares to the public.
The Form 8-A is an Exchange Act registration. In it, Canary states plainly that “an application for listing of the Shares of the Trust has been filed with and approved by The Nasdaq Stock Market LLC.”
Canary CEO Steven McClurg signed the document. You can read it directly on the SEC EDGAR system.
So the exchange side is now settled. Nasdaq has cleared the shares for listing, and the ticker INJC is locked in.
Here is the part that matters most. A listing approval under the Exchange Act is not the same as full clearance under the Securities Act.
The fund’s S-1 registration statement is still pre-effective. Canary filed the latest amendment around November 2, 2026, and that preliminary prospectus remains open.
Because the S-1 has not gone effective, the Canary Staked INJ ETF cannot sell shares to the public yet. Canary has not set a trading launch date either.
Injective’s own post framed the news as Nasdaq officially approving the first INJ staked ETF. The primary filings support the listing approval. Still, they do not show that the product is effective or tradable.
Key milestones for the Canary Staked INJ ETF
Canary submits an amended S-1 registration statement for its Staked INJ ETF.
Canary files Form 8-A confirming that Nasdaq approved the fund’s listing application. News coverage follows on November 5.
The fund must await S-1 effectiveness before selling shares to the public. Nasdaq listing approval alone does not clear this step.
Canary has not announced a launch date. Trading depends on S-1 effectiveness and completion of the remaining launch requirements.
The structure is a commodity-style trust, not a mutual fund. It holds INJ directly, and then it stakes most of that INJ to earn network rewards.
Canary Capital Group LLC sponsors the fund from Brentwood, Tennessee. BitGo acts as custodian and holds the private keys for the Trust’s INJ.
The Trust does not run its own validator. Instead, third-party providers selected by the sponsor handle the staking, while the custodian keeps control of the keys.
Fees come in two layers. First, the sponsor charges 1.10% a year on INJ holdings. Second, staking rewards split too. About 30% goes to fees shared by the provider, sponsor, and custodian. The fund then restakes the remaining 70% into its net asset value.
How INJC compares with spot and staked altcoin ETFs
“First-ever” context: The claim concerns a U.S. staked INJ ETF, rather than the first altcoin ETF or staking ETF. Nasdaq listing approval does not establish SEC effectiveness or confirm that INJC has begun trading.
INJC figures reflect the supplied preliminary filing and may change before launch.
Under normal conditions, the Trust intends to stake at least 90% of its INJ through those third-party providers. That is a high target for a regulated product.
But staking on Injective is not instant to unwind. The network uses a 21-day unbonding period, so holders cannot free staked tokens on demand.
To manage that, the fund keeps a liquidity buffer. This reserve covers share creations, redemptions, expenses, and asset protection while the bulk of the INJ stays staked.
Staking does carry risk. Slashing is one concern, though Injective set its slashing parameters to zero forfeiture as of mid-September 2026. Validator downtime and custody risk still apply, and no one guarantees the rewards.
INJ moved higher into the announcement window. The token climbed from the $7.0 to $7.3 area toward the high $7s. Reports on November 5 placed it near $8.00.
Aggregator trackers cited daily gains of about 8% to 12%, with 24-hour volume in the tens of millions. Treat these as approximate figures and verify them on primary chart platforms.
Network staking data stayed steady, though. According to Staking Rewards, INJ shows about a 7.54% reward rate and a 47% staking ratio. Roughly 58.25 million INJ sits staked today. No large shift traced directly to the news.
The next trigger is simple. The SEC must declare the S-1 effective before INJC can trade, and no date exists for that step yet.
Several unknowns also remain open. These include the specific staking providers and the final seed size. The sponsor could also tweak the fee or the 90% staking target.
Canary is not alone here either. Rivals such as 21Shares and REX-Osprey hold pending INJ applications. So the race for a live INJ product is still on.
For now, the Canary Staked INJ ETF holds a key approval but no ticker tape. Readers should watch the EDGAR filings for the moment the S-1 turns effective. This article is for information only and is not financial advice.
Our Crypto Talk is committed to unbiased, transparent, and true reporting to the best of our knowledge. This news article aims to provide accurate information in a timely manner. However, we advise the readers to verify facts independently and consult a professional before making any decisions based on the content since our sources could be wrong too. Check our Terms and conditions for more info.
Injective
